Clinical Trial

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 27, 2021 (before its estimated July 15, 2022 completion). Its status may not reflect the trial's current state.
Summary
The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-01-06; most recent amendment 2025-12-02.
Status change: Recruiting → Completed 2023-03-01
Status change: Not Yet Recruiting → Recruiting 2021-02-08
Trial Details
NCT Number NCT04700332
Lead Sponsor Hoag Memorial Hospital Presbyterian
Conditions Prostate Cancer
Enrollment 184 participants
Start Date 2021-02-01
Primary Completion 2022-07-15 (estimated)
Study Completion 2022-12-15 (estimated)
Updated on ClinicalTrials.gov 2021-07-27